Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
03
03
2023
accepted:
01
07
2023
medline:
18
9
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
Novel drug treatments for pediatric patients with cancer are urgently needed. Success of drug development in pediatric oncology has been promising, but many drugs still fail in translation from preclinical to clinical phases. To increase the translational potential, several improvements have been implemented, including the use of clinically achievable concentrations in the drug testing phase. Although pharmacokinetic (PK) parameters of numerous investigated drugs are published, a comprehensive PK overview of the most common drugs in pediatric oncology could guide preclinical trial design and improve the translatability into clinical trials. A review of the literature was conducted for PK parameters of 74 anticancer drugs, from the drug sensitivity profiling library of the INdividualized Therapy FOr Relapsed Malignancies in Childhood (INFORM) registry. PK data in the pediatric population were reported and complemented by adult parameters when no pediatric data were available. In addition, blood-brain barrier (BBB)-penetration assessment of drugs was provided by using the BBB score. Maximum plasma concentration was available for 73 (97%), area under the plasma concentration-time curve for 69 (92%), plasma protein binding for 66 (88%), plasma half-life for 57 (76%), time to maximum concentration for 54 (72%), clearance for 52 (69%), volume of distribution for 37 (49%), lowest plasma concentration reached by the drug before the next dose administration for 21 (28%), and steady-state concentration for 4 (5%) of drugs. Pediatric PK data were available for 48 (65%) drugs. We provide a comprehensive review of PK data for 74 drugs studied in pediatric oncology. This data set can serve as a reference to design experiments more closely mimicking drug PK conditions in patients, and may thereby increase the probability of successful clinical translation.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
904-913Informations de copyright
© 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Carai, S. et al. Childhood Cancer Inequalities in the WHO European Region (WHO Regional Office for Europe, Copenhagen, 2022) <https://apps.who.int/iris/bitstream/handle/10665/351857/9789289057615-eng.pdf?sequence=2&isAllowed=y>.
Butler, E., Ludwig, K., Pacenta, H.L., Klesse, L.J., Watt, T.C. & Laetsch, T.W. Recent progress in the treatment of cancer in children. CA Cancer J. Clin. 71, 315-332 (2021).
Barry, E. et al. Navigating the regulatory landscape to develop pediatric oncology drugs: expert opinion recommendations. Paediatr. Drugs 23, 381-394 (2021).
Pearson, A.D.J. et al. From class waivers to precision medicine in paediatric oncology. Lancet Oncol. 18, e394-e404 (2017).
de Tilburg, C.M. et al. The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 11, 2764-2779 (2021).
Allen, C.E. et al. Target and agent prioritization for the children's oncology group-national cancer institute pediatric MATCH trial. J. Natl. Cancer Inst. 109, 1-13 (2017).
Wong, M. et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat. Med. 26, 1742-1753 (2020).
Peterziel, H. et al. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ Precis. Oncol. 6, 94 (2022).
Jardim, D.L., Groves, E.S., Breitfeld, P.P. & Kurzrock, R. Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review. Cancer Treat. Rev. 52, 12-21 (2017).
Aldape, K. et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 16, 509-520 (2019).
Vassal, G. et al. International consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer. Mol. Cancer Ther. 20, 1462-1468 (2021).
Grossman, S.A. et al. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the adult brain tumor consortium's first workshop on CNS drug delivery. Neuro Oncol. 22, 1422-1424 (2020).
Begley, C.G. & Ellis, L.M. Drug development: raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
Page, M.J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
Gupta, M., Lee, H.J., Barden, C.J. & Weaver, D.F. The blood-brain barrier (BBB) score. J. Med. Chem. 62, 9824-9836 (2019).
R Core Team R: a language and environment for statistical computing (RStudio, PBC, Boston, MA, 2022).
R Studio team R Studio: Integrated Development Environment for R (2022).
Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, New York, 2016).
Sievert, C. Interactive Web-Based Data Visualization with R, Plotly, and Shiny (Chapman and Hall/CRC, Florida, 2020).
Paoletti, X., Geoerger, B., Doz, F., Baruchel, A., Lokiec, F. & le Tourneau, C. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. Eur. J. Cancer 49, 2392-2402 (2013).
Moreno, L. et al. Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. Nat. Rev. Clin. Oncol. 14, 497-507 (2017).
Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. & Kauffman, R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
Batchelor, H.K. & Marriott, J.F. Paediatric pharmacokinetics: key considerations. Br. J. Clin. Pharmacol. 79, 395-404 (2015).
Fernandez, E., Perez, R., Hernandez, A., Tejada, P., Arteta, M. & Ramos, J. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 3, 53-72 (2011).
Verscheijden, L.F.M., Koenderink, J.B., Johnson, T.N., de Wildt, S.N. & Russel, F.G.M. Physiologically-based pharmacokinetic models for children: starting to reach maturation? Pharmacol. Ther. 211, 107541 (2020).
CHMP Guideline on the guideline on the role of pharmacokinetics in the development of medicinal products in the pediatric population <https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-role-pharmacokinetics-development-medicinal-products-paediatric-population_en.pdf>. (2006).
Ecker, J. et al. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol. Commun. 3, 22 (2015).